Ventyx Biosciences (NASDAQ:VTYX) Shares Gap Down – Here’s What Happened

Ventyx Biosciences, Inc. (NASDAQ:VTYX)’s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $9.38, but opened at $8.88. Ventyx Biosciences shares last traded at $8.7330, with a volume of 921,308 shares.

Analyst Ratings Changes

VTYX has been the topic of a number of recent research reports. Oppenheimer lifted their price objective on Ventyx Biosciences from $9.00 to $14.00 and gave the company an “outperform” rating in a report on Monday, October 27th. Wells Fargo & Company increased their target price on Ventyx Biosciences from $11.00 to $14.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ventyx Biosciences in a research note on Wednesday, October 8th. HC Wainwright upgraded Ventyx Biosciences from a “neutral” rating to a “buy” rating and set a $18.00 price target on the stock in a research report on Wednesday, November 5th. Finally, Canaccord Genuity Group lifted their price objective on Ventyx Biosciences from $14.00 to $16.00 and gave the company a “buy” rating in a report on Friday, November 7th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Ventyx Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $15.50.

Ventyx Biosciences Stock Performance

The firm has a market capitalization of $592.99 million, a price-to-earnings ratio of -5.52 and a beta of 1.22. The business’s 50-day moving average is $6.52 and its two-hundred day moving average is $3.87.

Ventyx Biosciences (NASDAQ:VTYX) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.13. Analysts forecast that Ventyx Biosciences, Inc. will post -2.09 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in VTYX. Affinity Asset Advisors LLC acquired a new stake in Ventyx Biosciences during the second quarter worth approximately $9,707,000. Marshall Wace LLP acquired a new stake in Ventyx Biosciences during the 2nd quarter worth approximately $5,129,000. Redmile Group LLC grew its holdings in Ventyx Biosciences by 1,164.1% in the 1st quarter. Redmile Group LLC now owns 1,569,793 shares of the company’s stock valued at $1,805,000 after buying an additional 1,445,615 shares in the last quarter. Baker BROS. Advisors LP bought a new position in Ventyx Biosciences during the 3rd quarter worth $3,182,000. Finally, AQR Capital Management LLC lifted its holdings in shares of Ventyx Biosciences by 925.6% during the first quarter. AQR Capital Management LLC now owns 880,222 shares of the company’s stock worth $1,012,000 after buying an additional 794,401 shares in the last quarter. 97.88% of the stock is owned by institutional investors and hedge funds.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.